Business
ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug
ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced that the last patient has completed the final study visit in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating efficacy of Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.UTOPIA-1 trial is
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"UTOPIA-1 trial reaches last patient visit; results expected Q2","length":62,"tagName":"p","attribs":{}},{"type":"text","content":"SASKATOON, SK, April 16, 2026 /CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced that the last patient has completed the final study visit in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating efficacy of Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.UTOPIA-1 trial is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With the completion of the final study visit, the Phase 2a UTOPIA-1 trial has reached the last patient last visit milestone.","length":892,"tagName":"p"},{"type":"image","alt":"ZYUS Life Sciences Logo (CNW Group/ZYUS Life Sciences Corporation)","displaySize":"","headline":null,"caption":"ZYUS Life Sciences Logo (CNW Group/ZYUS Life Sciences Corporation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":162,"url":"https://media.zenfs.com/en/cnwgroup.com/55a80ac37859910ca4565cc9beb48abf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/M0.xHPqTjljdESz_OHkPmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4Ng--/https://media.zenfs.com/en/cnwgroup.com/55a80ac37859910ca4565cc9beb48abf","width":400,"height":162}},"href":"https://mma.prnewswire.com/media/2957831/ZYUS_Life_Sciences_Corporation_ZYUS_Life_Sciences_Announces_Comp.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are pleased to have completed patient participation in the UTOPIA-1 trial," said Dr. Julie Stakiw, Chief Medical Officer of ZYUS. "Cancer-related pain remains a complex condition to manage, and there remains a need for alternative treatment approaches. We look forward to evaluating the study results and thank the patients and investigators whose participation made this study possible."","length":412,"tagName":"p"},{"type":"text","content":""The completion of the last patient visit represents a key milestone fo...